PORT HUENEME, CA--(Marketwired - Jan 26, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (
The research poster presentation, titled "Development of a 20N Virus Filtration Process for Keyhole Limpet Hemocyanin (KLH) - A High Molecular Weight Protein," was authored by Stellar scientists Catherine Brisson, Ph.D., Laura Milbrandt, Zully Aguilar, and William Bailey. The presentation reported data from the Company's development and validation of filtration methods for the removal of viruses during manufacturing processes of KLH products.
KLH is often used as a carrier molecule and active ingredient in immunotherapies or as an injectable to assess immune effects of new drugs in clinical settings. The rising use of KLH in the clinical development of new immunotherapies highlights the need for appropriate purification methods including the implementation of a robust viral clearance step into the production process. However, due to the large size and complexity of the KLH molecule, development and optimization of viral clearance can be a challenge. At PepTalk, the Company presented results from its development of a nanofiltration method that demonstrated effective removal of the viruses evaluated in the study, and met suggested regulatory criteria for robustness.
Find Stellar's poster presentation here: http://bit.ly/1nu9vrK
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with governmental regulations; the timing of the Company's or its partners' anticipated results, including in connection with clinical trials; and other factors referenced in the Company's filings with securities regulators. For a discussion of further risks and uncertainties related to the Company's business, please refer to the Company's public company reports filed with the B.C. Securities Commission and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information contained in this press release.
Stellar Biotechnologies Company Contact:
Mark A. McPartland
Vice President of Corporate Development and Communications
Phone: +1 (805) 488-2800 ext. 103
The Ruth Group
Phone: +1 (646) 536-7013
The Ruth Group
Phone: +1 (646) 536-7006